Moxidectin is under consideration for development as a treatment for human scabies. As some arthropods show decreased sensitivity to moxidectin relative to ivermectin, it was important to assess this for assays showed that the concentration of moxidectin required to kill 50% of mites was lower than that of ivermectin (0.5 μM versus 1.8 μM at 24 h; < 0.0001). This finding provides further support for moxidectin as a candidate for the treatment of human scabies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527648 | PMC |
| http://dx.doi.org/10.1128/AAC.00381-17 | DOI Listing |
Publication Analysis
Top Keywords
treatment human
8
human scabies
8
efficacy moxidectin
4
moxidectin versus
4
versus ivermectin
4
ivermectin sarcoptes
4
sarcoptes scabiei
4
moxidectin
4
scabiei moxidectin
4
moxidectin consideration
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!